TRELEGY ELLIPTA (GlaxoSmithKline Australia Pty Ltd)
Product name
TRELEGY ELLIPTA
Date registered
Evaluation commenced
Decision date
Approval time
198 (255 working days)
Active ingredients
fluticasone furoate; umeclidinium bromide; vilanterol trifenatate
Registration type
EOI
Indication
Asthma
TRELEGY ELLIPTA (powder for inhalation) is now also indicated for the maintenance treatment of asthma in adult patient who are not adequately controlled with a combination of inhaled corticosteroid and a longacting beta2-agonist.